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Abstract
The establishment of human induced pluripotent stem cells (hiPSCs) has enabled the production of in vitro, patient-specific
cell models of human disease. In vitro recreation of disease pathology from patient-derived hiPSCs depends on efficient
differentiation protocols producing relevant adult cell types. However, myogenic differentiation of hiPSCs has faced
obstacles, namely, low efficiency and/or poor reproducibility. Here, we report the rapid, efficient, and reproducible
differentiation of hiPSCs into mature myocytes. We demonstrated that inducible expression of myogenic differentiation1
(MYOD1) in immature hiPSCs for at least 5 days drives cells along the myogenic lineage, with efficiencies reaching 70–90%.
Myogenic differentiation driven by MYOD1 occurred even in immature, almost completely undifferentiated hiPSCs, without
mesodermal transition. Myocytes induced in this manner reach maturity within 2 weeks of differentiation as assessed by
marker gene expression and functional properties, including in vitro and in vivo cell fusion and twitching in response to
electrical stimulation. Miyoshi Myopathy (MM) is a congenital distal myopathy caused by defective muscle membrane repair
due to mutations in DYSFERLIN. Using our induced differentiation technique, we successfully recreated the pathological
condition of MM in vitro, demonstrating defective membrane repair in hiPSC-derived myotubes from an MM patient and
phenotypic rescue by expression of full-length DYSFERLIN (DYSF). These findings not only facilitate the pathological
investigation of MM, but could potentially be applied in modeling of other human muscular diseases by using patient-
derived hiPSCs.
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Introduction
The establishment of human induced pluripotent stem cells
(hiPSCs) [1,2] has paved the way for the generation of patient-
specific stem cell resources. Directed differentiation of pluripotent
stem cells into a variety of cell types provides a powerful tool for
in vitro disease modeling [3]. Although the number and genetic
diversity of patient-derived hiPSC lines continues to increase, the
difficulty of differentiating hiPSC into mature cell types remains
a major obstacle in understanding disease.
Effective differentiation into affected cell types is a critical step
in the production of in vitro disease models from hiPSCs. In the
case of myopathies, significant efforts have been made to generate
skeletal muscle cells from human pluripotent stem cells [4,5,6].
However, previously reported differentiation protocols suffer from
complex time-consuming procedures, low differentiation efficien-
cies, and/or low reproducibility. Reproducibility is perhaps the
greatest hurdle facing robust differentiation protocols from human
pluripotent stem cells, especially considering the high levels of
clonal variation previously reported [7].
Directed myogenic differentiation of adult somatic cells
mediated by the master transcriptional factor, MYOD1 [8,9],
was initially established in 1987 [8]. Following this first demon-
stration, various types of cells have been shown to give rise to
myocytes in response to forced expression of MYOD1 [9,10,11],
including hiPSC-derived fibroblasts treated with MYOD1 mRNA
[12]. Considering the inherent potential of hiPSCs, differentiation
into fibroblasts prior to myogenic induction is a redundant step.
Recently, Tedesco et al. showed that hiPSC-derived mesoangio-
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blast-like stem/progenitor cells can be converted into myocytes by
tamoxifen-induced MYOD-ER overexpression [13]. Goudenege
et al. also showed that hiPSC-derived mesenchymal cells can be
promoted to myogenic differentiation efficiently by Adenoviral-
transduction mediated MYOD1 overexpression [14]. The 2 reports
both indicated that iPSC-derived mesodermal or mesenchymal
cells, both of which are differentiated for more than 2 weeks from
undifferentiated hiPSCs, have a high potential for myogenic
differentiation in response to MYOD1 overexpression. However,
such differentiation steps prior to MYOD1 transduction might
contribute to the reported observation of low reproducibility.
Because mouse embryonic stem cells (mESCs) are able to directly
differentiate to myocytes in response to Tetracycline (Tet)-induced
MYOD1 expression [15], we assessed whether drug-induced
MYOD1 expression could similarly promote efficient myocyte
differentiation directly from undifferentiated hiPSCs. Here, we
demonstrate that MYOD1 overexpression in immature hiPSCs
drives them to mature as myocytes with very high efficiency and
reproducibility within 2 weeks.
Miyoshi myopathy [16] (MM) is a congenital distal myopathy
caused by defective muscle membrane repair as a result of
mutations in DYSFERLIN [17,18]. Research directed at un-
derstanding the MM pathology has been primarily performed
using model mice. To evaluate the true pathology of human
disease, it is important to exploit current iPSC technology for
direct assessment of patient samples. Here, we apply our
differentiation technique to MM-disease modeling, recapitulating
disease pathology in vitro, and successfully rescue the phenotype of
MM by gene repair. The differentiation method presented here is
suitable for muscular disease modeling by using patient-derived
hiPSC. Our method of MYOD1-induced myogenic differentiation
directly from undifferentiated hiPSCs is also suitable for the
establishment of drug screening systems by using patient-derived
hiPSCs. This is due to the unlimited proliferation potential of
hiPSCs and uniformity in the undifferentiated state, which may
prevent variation in differentiation frequency.
Results
Generation of hiPSCs with Drug-inducible MYOD1
Expression
We constructed a self-contained, drug-inducible expression
vector, based on the piggyBac (PB) transposon [19]. This vector
constitutively expresses the neomycin (G418) resistance gene along
with the rtTA transactivator element, which mediates doxycycline
(Dox)-dependent activation of cDNA cassettes controlled by tetO
promoter (PB-TAC-ERN; Fig. 1a). Activation of gene expression
in response to Dox may be indirectly monitored by co-incident
mCherry activation. Using Gateway cloning, we produced a de-
rivative vector containing the human MYOD1 gene (Tet-MyoD1).
The Tet-MyoD1 vector was transfected together with PB
transposase (PBase) into 3 independent hiPSC lines, and selected
in G418 supplemented media for 5 days to generate pooled
MyoD-hiPSCs containing genomic transposon integrations
(Fig. 1b). In these pooled MyoD-hiPSCs, Dox administration
for 24 h robustly induced MYOD1 expression as detected by
mCherry fluorescence and MYOD1 protein (Fig. 1c). As some
cells did not express mCherry, we selected appropriate MyoD-
hiPSC clones with robust, uniform levels of mCherry induction for
further analysis. These clones retained pluripotency, which was
confirmed by their expression of surface markers (Fig. S1a) and
gene characteristic of an undifferentiated state (Fig. S1b), as well
as teratoma formation (Fig. S1c). These clones were selected by
the high expression of mCherry after Dox administration (Fig.
S2a). RT-PCR analysis of these clones confirmed undetectable
exogenous MYOD1 background expression in the absence of Dox,
whereas Dox treatment strongly induced exogenous MYOD1
within 48 h, in correlation with mCherry expression (d2).
Importantly, despite continued maintenance in hiPSC culture
conditions, endogenous MYOD1 activation was detectable after
96 h (d5) of Dox induction, with the effect being reproducible in
MyoD-hiPSC clones derived from 3 distinct hiPSC lines: 201B7,
253G1, and 254G4 [1] (Fig. S2b). In selected MyoD-hiPSC
clones, mCherry expression was detected uniformly 24 h after Dox
administration in hiPSC-maintenance conditions (Fig. 1d). When
the addition of Dox was continued for 7 days under hiPSC-
maintenance conditions, the emergence of myosin heavy chain
(MHC) [20] positive cells was extremely limited to the edge of
MyoD-hiPSC colonies, and many MyoD-hiPSCs lines retaining
undifferentiated colonies (Fig. 1d). On the other hand, when the
culture medium was exchanged for differentiation medium on d1,
MyoD-hiPSCs were differentiated into MHC positive myocytes
disrupting colony formation. This medium replacement resulted in
highly efficient myogenic induction (Fig. 1e). These results suggest
that extended expression of transgenic MYOD1 was able to
activate the myogenic differentiation program in undifferentiated
hiPSCs, even under sub-optimal conditions.
Dox-induced Myogenic Differentiation of MyoD-hiPSCs
As MyoD-hiPSCs maintained an undifferentiated status in
hiPSC maintenance medium (Fig. 1d), we sought to optimize the
differentiation protocol by adjusting culture conditions to be more
appropriate for myogenic induction; first removing basic-fibroblast
growth factor (b-FGF) for spontaneous differentiation, and then
changing to alpha Minimal Essential Medium (aMEM) supple-
mented with a low concentration (5%) of knockout serum
replacement (KSR). Dox treatment was maintained throughout
the analysis. Early medium replacement to low-KSR aMEM
enhanced myogenic differentiation, whereas late replacement did
not improve differentiation compared to continued culture in
hiPSC maintenance media without bFGF (Fig. 2a). Media
containing a low concentration of horse serum has been shown
to promote the maturation of myoblast into myotubes [9,21]. To
examine this later stage of differentiation, we assessed the effect of
serum on the maturation of Dox-induced myogenic cells by
counting the number of nuclei per myotube on d9. Although the
difference was not statistically significant, a tendency towards
higher numbers of nuclei was detected in hiPSCs cultured in 5%
horse serum as compared to 5% KSR (Fig. 2b).
We predicted that the initiation point and period of Dox
administration could also have an effect on differentiation
responses. Dox addition at day 1 (d1) of differentiation (24 h after
bFGF removal) induced over 90% mCherry positive cells.
However, Dox addition later on in the differentiation protocol
(d4) revealed an unresponsive, mCherry negative population
(Fig. 2c, d), suggesting a failure of the expression vector to
activate in a proportion of partially differentiated cells. To assess
whether fully differentiated hiPSCs can be promoted into
myogenic differentiation by Dox-mediated MYOD1 expression,
we applied our system to mesenchymal progenitor cells, known as
SB-outgrowth cells (SB-OGs) [5], derived from hiPSCs. According
to the report of Mahmood et al, SB-OGs derived from MyoD-
hiPSCs were established after 14 days of differentiation, and were
passaged twice [5]. When Dox was administrated to SB-OGs
cultures, low levels of mCherry expression were observed,
indicating low myogenic differentiation efficiency (Fig. S3a, b).
Taken together, these results indicate that our inducible gene
expression system using the piggyBac vector is suitable for driving
Efficient Muscle Induction from Diseased hiPSC
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the expression of genes in undifferentiated hiPSCs, rather than
those which have been differentiated. However, Dox administra-
tion at the initiation of differentiation (d0; coincident with the
change to low-serum media) led to lower cell survival (data not
shown). Therefore, Dox administration was initiated at the fixed
time point, d1, in our system. Next, we examined the period of
Dox administration. MyoD-hiPSCs did not differentiate into
myocytes following less than 3 days of Dox administration
(Fig. 2e). Beyond 5 days of administration, continued Dox
treatment did not significantly enhance the induction of MHC
positive myocytes (Fig. 2e), revealing that 5–6 days of Dox
administration was sufficient to commit MyoD-hiPSCs to a myo-
genic lineage. Next, we investigated the effect of initiating Dox
administration on various days. Although Dox administration on
d0 resulted in a large amount of cell deaths, early Dox
administration resulted in highly efficient differentiation (Fig.
S3c, d). Using these optimized parameters, we established
a standardized protocol for myogenic differentiation of MyoD-
hiPSCs (Fig. 3a).
Applying this differentiation protocol, all MyoD-hiPSC clones
derived from 3 distinct parental hiPSC lines could be promoted to
form MHC positive myotubes (Fig. 3b). The efficiency was
calculated from the percentage of MHC positive cells among total
cells, and consistently ranged from 70% to 90%, irrespective of the
clone of origin (Fig. 3c). Differentiated MyoD-hiPSCs changed
their shape to spindle-like, uniformly (Movie S1). Thus, dominant
drug-regulated expression of exogenous MYOD1, combined with
our differentiation culture conditions overcomes clonal variation,
and actualizes efficient and uniform myogenic differentiation.
Differentiation of Myocytes from MyoD-hiPSCs Occurs
Directly
To characterize cell responses to this updated differentiation
protocol, we analyzed the time course of gene expression of both
Figure 1. Generation of MyoD-hiPSCs. (a) Construction of the Tet-inducible MYOD1 expressing piggyBac vector (Tet-MyoD1 vector). (b) A
scheme of generation of MyoD-hiPSCs. Human iPSCs were transfected the Tet-MyoD1 vectors with transposase by lipofection. To select transfected
cells, G418 were added for 5 days in the hiPSC culture media at 2 days after transfection. (c) MyoD-hiPSCs after 24 h in culture with or without Dox
administration. Scale bar = 20 mm. (d) Upper lanes show dox-added MyoD-hiPSCs at d1. Lower lanes show immunodetection of MHC in Dox-induced
MyoD-hiPSCs at d7. A lower-left panel shows the cells differentiated in maintenance medium from d1 to d7. A lower-right panel shows the cells
differentiated in aMEM containing 5% KSR from d1 to d7. Scale bars = 200 mm. (e) Percentage of MHC positive cells per total cells following MyoD-
induced differentiation. **p,0.01.
doi:10.1371/journal.pone.0061540.g001
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undifferentiated and myogenic markers in the presence or absence
of Dox (Fig. 4a). Expression of mCherry, synonymous with
exogenous MYOD1 expression, was the highest at d2 and declined
throughout the protocol. As expected, the expression of markers of
the undifferentiated markers [22], such as OCT3/4, SOX2 and
NANOG, gradually decreased through the course of differentiation
(Fig. 4a, gray bars). The expression of endogenous MYOD1 and
MYOGENIN [23], both of which are directly and positively
regulated by MYOD1, appeared at d3 and peaked at d7 (Fig. 4a,
gray bars). Furthermore, mature myofiber markers such as
creatine kinase muscle isoform (CK-M) [24] and DYSTROPHIN (DMD)
[25], were also detected following exogenous MYOD1 expression
(Fig. 4a, gray bars). By contrast, prolonged expression of genes
characteristic lacking differentiation and an absence of myogenic
gene expression were observed in the absence of Dox administra-
tion (Fig. 4a, black bars). Similar to observations in mouse
ESCs [15], Dox-induced MYOD1 expression in hiPSCs is
sufficiently potent to directly promote myogenic differentiation,
even in completely undifferentiated cells. In development,
myogenic cells derive from a progenitor of mesodermal origin.
Figure 2. Optimization of Differentiation Conditions. (a) Percentage of MHC positive myogenic cells derived from MyoD-hiPSCs during 9 days
differentiation with various timing of medium replacement. *p,0.05 (b) The average number of nuclei of myofibers in each condition of 5% KSR or
5% HS containing media after 7 days differentiation. (c) Flow cytometric analysis of MyoD-hiPSCs with 24 h Dox treatment in different start points.
Dox addition at differentiation d1 promoted higher percentage of mCherry expression in MyoD-hiPSCs than Dox addition at differentiation d4. (d) A
merged image of phase-contrast and mCherry images in differentiated MyoD-hiPSCs which were administrated Dox at differentiation d4. Some
MyoD-hiPSCs turned to be unresponsive with Dox, indicating no mCherry expression area (dotted line). Scale bar = 100 mm. (e) MHC positive
myogenic cell number derived from MyoD-hiPSCs during 11 days differentiation with various administration periods of Dox. *p,0.05.
doi:10.1371/journal.pone.0061540.g002
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To further assess whether Dox-induced myogenic differentiation
proceeded via mesodermal differentiation, expression of mesoder-
mal marker genes was analyzed. The pan-mesodermal marker
BRACHYURY (T) [26], paraxial mesodermal markers MESP2 [27]
and TBX6 [28], and a dermomyotome marker PAX3 [29] were
expressed transiently during Dox-induced differentiation, whereas
in the absence of Dox very low expression of mesodermal genes
was observed (Fig. S4). To determine whether mesodermal gene
expression is essential for myogenic differentiation in our system,
siRNA was used to suppress T or TBX6 during the early phase of
differentiation. Expression of T or TBX6 was strongly suppressed
on d3 and d5 by 48 h of pretreatment with siRNA (Fig. S5a, b).
Furthermore, both T and TBX6 siRNA treatments indirectly
suppressed expression of PAX3, which is upstream ofMYOD1 [30].
Despite suppression of mesodermal gene expression, efficiencies of
myogenic differentiation were not affected (Fig. S5c, d). Thus,
although several mesodermal genes express transiently, MyoD-
hiPSCs successfully differentiate along a myogenic lineage in-
dependent of these factors, seemingly circumventing a mesodermal
intermediate stage.
Myocytes Derived from MyoD-hiPSCs Resemble Mature
Myocytes in vivo
To assess myogenic properties of differentiated MyoD-hiPSCs,
histological and gene expression analyses were performed.
Although undifferentiated hiPSCs had few mitochondria, differ-
entiated MyoD-hiPSCs had many mitochondria surrounding their
nuclei (Fig. 4b). Furthermore, differentiated MyoD-hiPSCs
expressed the mature myocyte markers, DYSTROPHIN, skeletal
muscle Actin and CK-M (Fig. 4c). Skeletal muscle Actin does not
appear in cardiac muscle and is therefore used to distinguish
skeletal myocytes from cardiomyocytes. These features suggest
that Dox-induced myogenic cells derived from MyoD-hiPSCs
have characteristics of mature myocytes. To further define
myogenic cell identity, we analyzed global gene expression profiles
of differentiated MyoD-hiPSCs, comparing these with the
differentiated immortal human myoblast cell line Hu5/E18
[31,32], and undifferentiated hiPSCs (Fig. 4d, e). The microarray
profiles of differentiated MyoD-hiPSCs were similar to those of
differentiated Hu5/E18 and quite divergent from those of
undifferentiated hiPSCs (Fig. 4d). Multiscale bootstrap clustering
analysis showed that MyoD-hiPSCs derived myocytes had
statistically significant different gene expression profiles from those
of undifferentiated hiPSCs and similar gene expression profiles to
those of Hu5/E18 derived myocytes (Fig. S6). Furthermore, we
selected specific genes associated with muscle differentiation and
analyzed mRNA expression profiles. Differentiated MyoD-hiPSCs
showed high expression levels of the selected muscle associated
genes, similar to differentiated Hu5/E18 cells (Fig. 4e), with the
exception of MYF5 [33], an upstream transcription factor
regulating MYOD1 (Fig. 4e). These data were confirmed by
quantitative real time PCR. Consistent with the results of
microarray analysis, myogenic transcription factors such as
MYOD1, MYOGENIN, MEF2C [34] and SIX1 [35], which are
downstream genes of MYOD1, were upregulated in induced cells
but not in undifferentiated cells. By contrast, MYF5, which is an
upstream gene of MYOD1, was not upregulated in induced cells
(Fig. S7). Taken together, Dox-induced myogenic cells generated
from MyoD-hiPSCs appear to represent mature myocytes similar
to differentiated human myoblasts. Yet, unlike human myoblasts,
MyoD-hiPSCs do not express MYF5, and may transit directly
from undifferentiated into MYOD1 positive myogenic cells.
Figure 3. Reproducible myogenic differentiation with the optimized protocol. (a) A schematic of our muscle differentiation protocol
beginning with MyoD-hiPSCs. (b) Immunohistochemistry of differentiated MyoD-hiPSCs for MHC (red). Scale bar = 100 mm. (c) Percentage of MHC
positive cells per total cells following MyoD-induced differentiation of 6 MyoD-hiPSC clones. (n = 3 for each clone). Data are listed as mean 6S.D.
doi:10.1371/journal.pone.0061540.g003
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Figure 4. Characterization of myofiber derived from MyoD-hiPSCs. (a) Time course gene expression profile for undifferentiated and
myogenic markers in B7 #9 MyoD-hiPSC clone with (gray bars) or without (black bars) Dox administration (n = 3). Data are listed as mean6S.D. The
Efficient Muscle Induction from Diseased hiPSC
PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e61540
Functional Properties of Dox-induced Myocytes Derived
from MyoD-hiPSC
Structural analysis by electron microscopy revealed that
differentiated MyoD-hiPSCs have myofibrils containing future Z
line-like structures, and myosin fibers similar to differentiated
Hu5/E18 (compare Fig. 5a, b). To assess whether such structural
properties are sufficient to mediate contraction, Dox-induced
myogenic cells were electrically stimulated. As predicted, MYOD1
induced myotubes could contract coincident with electrical pulses
(Movie S2). Another discriminating characteristic of myogenic
cells is cell fusion, leading to multi-nucleated myotubes. With
regard to fusion potential, differentiated MyoD-hiPSCs were co-
cultured with the mouse myoblast cell line C2C12 [21],
engineered to express GFP. MyoD-hiPSCs were induced towards
myogenic differentiation for 7 days. On d7, C2C12 cells were
seeded onto induced MyoD-hiPSCs. Two days after co-culture,
mCherry positive human myogenic cells fused with GFP positive
murine myogenic cells were identified by time lapse photography
(Fig. 5c and Movie S3). Several days later, immunohistochem-
istry revealed that a number of human nuclei in murine myotubes,
confirming cell fusion in vitro (Fig. 5d). Finally, we transplanted
differentiated MyoD-hiPSCs into tibialis anterior muscles (TA
muscle) of non-obese diabetic/severe-combined immunodeficient-
duchenne muscular dystrophy null (NOD/scid-DMD) mice [36]
(Methods). On d28 after transplantation, although the number of
signals was a few, specific staining with anti-human spectrin (Fig.
S8a) and anti-human dystrophin (Fig. S8b) was detected in
mouse TA muscles. These results indicate that MyoD-hiPSC-
derived myocytes display fusion potential both in vitro and in vivo.
Taken together, Dox-induced myogenic cells derived from MyoD-
hiPSCs achieve the functional properties of muscle, similar to
differentiated human myoblasts.
Application of Myogenic Differentiation to Disease
Modeling
We applied our myogenic induction system to assess the utility
of these differentiated cells in modeling the human disease Miyoshi
myopathy (MM) [16]. MM hiPSCs were generated from MM
patient fibroblasts by transduction of the 4 Yamanaka factors
(OCT4, SOX2, KLF4 and c-MYC) with Sendai virus (SeV) vectors
(Methods). Subsequently, we introduced the Tet-MyoD1 vector
into MM hiPSCs, and chose 2 independent clones (MyoD-MM
#5 and #6) for further analysis. These 2 clones were morpho-
logically identical to the other hiPSCs (Fig. 6a), expressed
endogenous pluripotency marker genes without detectable persis-
tence of the SeV viral RNA genome (Fig. 6b), and formed
teratomas in vivo (Fig. S9). MyoD-MM hiPSCs were unhindered
in their ability to differentiate into MHC or MYOGENIN positive
mature myocytes (Fig. 6c). Yet, differentiated MyoD-MM cells
demonstrated impaired expression of DYSFERLIN [17,18], as
expected from the primary genetic lesion (Fig. 6d, lanes 1, 2).
Thus, we derived rescued MyoD-MM+Dysf hiPSC clones by
stable transgenic over-expression of DYSFERLIN, and confirmed
DYSFERLIN expression in 2 rescue clones and the MyoD-B7 #9
control line by western blotting (Fig. 6d).
To recreate pathological conditions, we assessed membrane
repair function in both diseased and DYSFERLIN-rescued
MyoD-MM hiPSCs compared to control MyoD-hiPSCs
(Fig. 6e, f). A myotube from MyoD-MM clone #5 displayed
extensive uptake of FM1-43 in all cytoplasmic lesions, indicating
defective membrane repair following two-photon laser-induced
injury of the sarcolemma [17] (Fig. 6e left, Movie S4). In
contrast, myotubes from MyoD-MM #5+ Dysf and MyoD-B7 #9
control cells display focal uptake of FM1-43 at the damaged area
(Fig. 6e center and right panels, Movie S5 and S6). Indeed,
the apparently unimpeded uptake of FM1-43 observed in MM
patient-derived myotubes, was reversed by over-expression of
DYSF, suggesting efficient membrane resealing, similar to control
cells (Fig. 6f). Thus, in vitro differentiated MM patient iPSCs
faithfully recapitulated the expected pathological condition, which
could be reversed by overexpression of the affected gene product,
suggesting a possible treatment for MM by using gene therapy.
Discussion
Over the years, engineered model mice have been the mainstay
in understanding disease pathology [36,37,38]. Yet, due to
discrepancies between mouse phenotypes and actual human
disease pathology [39], it would be preferable to evaluate disease
and perform in vitro screening for potential therapeutics in a reliable
human system. In considering in vitro disease modeling and
screening, large numbers of cells are necessary to generate and
reproduce experimental data. Fibroblasts and many other somatic
cells are not able to proliferate indefinitely and quickly reach
senescence, failing to maintain a similar level of quality throughout
their limited replicative lifespan. As hiPSCs have a clear advantage
as an indefinitely self-renewing cell source for in vitro assays, iPSC
technology coupled with robust in vitro differentiation has been
hailed as a major breakthrough in the field [40]. Myogenic
induction from hiPSCs, following the protocols outlined here,
provides consistent quality, exhibiting higher efficiency and
reproducibility than described in previous reports [10,12], whereas
the period required for induction is as short as 10 days. These are
significant improvements and represent major steps towards iPSC-
based disease-modeling and drug screening for myogenic dis-
orders.
Although forced expression ofMYOD1 by mRNA treatment can
induce myocytes from hiPSCs-derived fibroblasts, the efficiency of
myogenic differentiation is limited to less than 40% [12]. This may
in part be due to a low efficiency of mRNA transfection in
fibroblasts. In contrast, the piggyBac vector system employed here
presents advantages in obtaining transgenic hiPSCs through
efficient and stable genomic integration, a suitable approach for
in vitro applications. Transgenic hiPSC populations or clones
carrying the piggyBac vector may be easily purified before Dox
induction by using simple drug selection. Clones derived in this
manner display robust and uniform drug-induced transgene
activation through the early stages of differentiation, ensuring an
effective and coordinated response, and thus achieving efficiencies
in excess of 70%. Furthermore, the piggyBac Tet-inducible gene
expressing vector is almost completely inactive in partially or fully
data were standardized by b-actin using teratoma. The data on d0= 1 in undifferentiated markers, such as OCT3/4, SOX2 and NANOG. The data on
d7= 1 in other analyses. *: p,0.05, **: p,0.01, respectively, between Dox(–) and Dox(+). (b) Intracellular localization of mitochondria in both
undifferentiated and differentiated MyoD-hiPSCs. Scale bar = 20 mm. (c) Immunohistochemistry of differentiated MyoD-hiPSCs for mature myogenic
markers, such as CK-M, creatine kinase muscle isoform, Skeletal muscle Actin, and DYSTROPHIN. Scale bar = 20 mm. (d) Heat map of global mRNA
expression comparing undifferentiated hiPSC (sample 1) and differentiated myogenic cells (samples 2-5). (e) Myogenic gene profile and unsupervised
clustering based on markers associated with myofibers for undifferentiated hiPSCs and differentiated myogenic cells. Red color indicates up-
regulated genes and blue color indicates down-regulated genes in (d) and (e).
doi:10.1371/journal.pone.0061540.g004
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differentiated hiPSCs, but expresses strongly in undifferentiated
hiPSCs. By initiating differentiation using the master regulator,
MYOD1, in homogenous undifferentiated hiPSCs, rather than
a heterogenous differentiated cell population, our approach
achieves highly consistent efficiency. Recently, several reports
have demonstrated highly efficient myogenic differentiation of
hiPSCs driven by the overexpression of transcription factors
[6,13,14]. Darabi et al. showed that PAX7-overexpression in
mesodermal cells differentiated from hiPSCs through embryoid
body formation, could promote efficient myogenic differentiation
and generate transplantable myogenic progenitors which were
applicable for muscle regeneration. However, their method of
differentiation entailed many complicated steps including cell
sorting by flow cytometer, and the time taken to induce mature
myocytes was more than 4 weeks [6]. Tedesco et al. demonstrated
that human iPSC-derived mesoangioblast-like progenitors
(HIDEMs) could be generated by a 3 weeks, multi-step
differentiation method. Although, the HIDEMs were able to act
as transplantable myogenic progenitors, with excellent regenera-
tion potentials in impaired muscle, they had poor myogenic
Figure 5. Functional assay for differentiated MyoD-hiPSCs. (a, b) Electron microscopy of differentiated MyoD-hiPSCs (a) and differentiated
human myoblast Hu5/E18 cells (b). Red arrows indicate myofibrils. Black arrowheads indicate future Z lines. Black arrows indicate myosin fibers. Scale
bars = 500 nm. (c) Serial photographs of differentiated MyoD-hiPSCs co-cultured with C2C12 cells. A hiPSC-derived mCherry+ cell (white arrow) fused
with a mouse-derived GFP+ cell (white arrowhead) resulting in a yellow cell (red arrow). Time increments between images = TIME. Scale bar = 100 mm.
(d) Immunohistochemistry of MyoD-hiPSCs co-cultured with C2C12 cells. White arrows indicate human nuclei in a GFP+ murine myofiber. Scale
bar = 100 mm.
doi:10.1371/journal.pone.0061540.g005
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differentiation potential in vitro; efficient in vitro myogenic in-
duction of the HIDEMs depended on forced expression of
MYOD1 from a tamoxifen-inducible lenti-viral vector system
[13]. Goudenege et al. demonstrated that efficient myogenic
differentiation could be induced from hiPSC-derived mesenchy-
mal cells by adeno-viral transduction of MYOD1 [14]. The use of
an integration-free adenoviral system could be advantageous for
muscular disease cell therapy, but it could potentially be
a complicated step during establishment of drug screening
platforms following disease modeling. In all 3 previously reported
procedures, hiPSCs were differentiated into mesodermal or
mesenchymal progenitors prior to forced expression of the
transcription factors. Although, these procedures able to induce
myogenic progenitors for use in cell therapy, pre-differentiation
steps, with serum-containing medium, could increase the clonal
variation of hiPSCs, and consequently affect the reproducibility of
Figure 6. Modeling Miyoshi Myopathy (MM) by patient derived-hiPSCs. (a) Morphology of patient derived MM-hiPSC clones, expanded
following G418 selection for Tet-MyoD1 vector transposition. Scale bar = 200 mm. (b) RT-PCR analysis of endogenous pluripotent stem cell markers in
MyoD-MM hiPSCs. (c) Efficient myogenic differentiation of MyoD-MM hiPSCs according to the protocol defined in Figure 3a. MHC positive (left), or
Myogenin positive (right) cells were observed dominantly. Scale bars = 100 mm. (d) DYSFERLIN expression of the myofibers from MyoD-MM hiPSCs
(lane 1, 2), rescued MyoD-MM hiPSCs which expressed full-length DYSF cDNA driven by EF1a promoter (lane 3, 4), and control non-diseased MyoD-
hiPSCs (lane 5) confirmed by western blotting. ACTB=b-actin. (e) Entry of FM1-43 green fluorescent dye into differentiated myofibers from MyoD-MM
#5 (left), rescued MyoD-MM #5 with DYSF expression (middle), or control MyoD-hiPSC clone B7 #9 (right), before (0 s) and 20 s after (20 s) two
photon laser-induced damage of the sarcolemmal membrane (arrow). Scale bars = 20 mm. (f) Summary time course data of accumulation of FM1-43
dye in laser-damaged myofibers derived from B7 #9 (black circles), MyoD-MM hiPSCs (red or blue triangles) and rescued MyoD-hiPSCs with
DYSFERLIN expression (red or blue circles). n = 5 for each clone. Data are listed as mean 6S.E.
doi:10.1371/journal.pone.0061540.g006
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the methods. By contrast, we initiated differentiation in un-
differentiated hiPSCs, which are relatively homogenous, and our
simple method exhibits high reproducibility. Therefore, our
method has advantages for application in drug screening following
muscular disease modeling by using patient-derived hiPSCs, as
a simple, rapid, and reproducible myogenic differentiation pro-
tocol, compared to previously reported methods.
Recently, it was revealed that premyogenic mesodermal genes
are activated by transgenic expression of MYOD1 in undifferen-
tiated mouse embryonal carcinoma cells [11]. In our hiPSC
differentiation method, exogenous MYOD1 acts as a dominant
regulator of myogenesis, through activation of recognized mature
myogenic gene networks, presumably without requiring stepwise
mesodermal differentiation as occurs during embryonic develop-
ment. We confirm that exogenous expression of MYOD1 in
undifferentiated hiPSCs can indeed promote premyogenic meso-
dermal gene expression. However, our knockdown experiments
suggest that premyogenic mesodermal gene expression is dispens-
able, and that the majority of the undifferentiated hiPSC
population can be directly differentiated into mature myocytes.
This observation supports our hypothesis that Dox-induced
MYOD1 expression in hiPSCs directly activates the myogenic
gene network independent of premyogenic mesodermal genes.
Myocytes induced from hiPSCs with MYOD1 demonstrate
similar global gene expression patterns and microstructures to the
immortal human myoblast cell line Hu5/E18. Moreover, induced
myocytes acquire mature functional properties such as cell fusion
and twitching on electrical stimulation. This report is the first to
present such detailed analysis for the functional properties of
induced myocytes, which will be absolutely critical in attaining
reliable muscular disease modeling. We applied our system to
rproduce pathological conditions of MM by using patient-derived
hiPSCs. We observed defective membrane repair in MM hiPSC-
derived myotubes after two-photon laser-induced injury of the
sarcolemma, and rescued this phenotype by transgenic expression
of full-length DYSF. It is still unclear why defective membrane
repair may result in chronic muscle inflammation in MM patients.
Importantly, DYSFERLIN is also expressed in immune cells [41],
and there is some debate as to which cell lineage (myocytes or
immune cells) is responsible for the pathology of MM. As immune
cells may be differentiated directly from iPSCs [42], this question
may be addressed by co-culture of healthy iPSC-derived immune
cells and MM patient iPSC-derived myocytes, or vice versa. In this
context, our differentiation system should prove useful in deriving
enriched myocyte populations for co-culture, and help to resolve
the remaining questions regarding MM pathology.
Myogenic differentiation of hiPSCs provides clear advantages
over the use of disease myocytes or fibroblasts in recreating
pathological conditions, and the in vitro study of myogenic
disorders. Our defined differentiation system provides reproduc-
ibility, high efficiency and short induction periods. These
properties could help promote the establishment of human
muscular disease models, which would eventually lead to a better
understanding of disease development. Furthermore, drug-screen-
ing platforms based on human cells will help resolve incongruent
drug treatment efficacies observed between mice and human,
hopefully leading to prospective treatments and eventually cures.
Methods
Cell Culture
Human iPSC lines 201B7, 253G1 and 253G4 were kindly
provided by Dr. Shinya Yamanaka [1]. Human dermal fibroblasts
used for generating 201B7 and 253G4 were purchased from Cell
Applications, Inc. All human iPS cells were established according
to procedures approved by the Ethics Committee on Human Stem
Cell Research of the Institute for Frontier Medical Sciences, Kyoto
University. The ethics committee approved our studies. The
hiPSCs were cultured in human iPS medium composed of primate
ES medium (ReproCELL) supplemented with 4 ng/mL recombi-
nant human basic fibroblast growth factor (bFGF, Wako), and
otherwise maintained as previously described [1]. The immortal-
ized human myoblast cell line Hu5/E18 provided by RIKEN
BRC through the National Bio-Resource Project of the MEXT,
Japan, was maintained and differentiated as described previously
[32].
Generation of an iPS Cell Line Derived from a Patient
with Miyoshi Myopathy (MM)
Studies were approved by the authors’ Institutional Review
Board and conducted under the Declaration of Helsinki. MM
patient information was encoded to protect privacy, and written
informed consent obtained. The MM patient was known to have 2
mutations in the DYSF gene. Fibroblasts from the patient were
cultured from skin biopsy explants under protocols approved by
the Ethics Committee on Human Stem Cell Research of the
Graduate School of Medical Sciences, Kumamoto University. The
ethics committee specifically approved these studies. The patient
provided written informed consent to participate in these studies.
Skin samples were minced and cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM; Invitrogen) supplemented with 10%
fetal bovine serum (Invitrogen). Patient-derived hiPSCs were
generated with SeV as described previously [43] and are referred
to herein as MM-hiPSCs.
Generation of a Doxycycline-inducible MyoD-hiPS Cell
Line
A cDNA clone of MYOD1 was purchased from MGC clone
(Invitrogen, MGC:71135, GenBank: BC064493.1). The coding
region of MYOD1 was PCR cloned into pENTR Directional
TOPO (Invitrogen) according to the manufacturer’s protocol. The
PB-TAC-ERN (KW111) vector was assembled with standard
cloning methods by using PB-TET [19] as a backbone. The bgeo
reporter in PB-TET was swapped for mCherry, and a constitutive
rtTA-neo expression cassette inserted. pVITRO1-neo (InvivoGen)
was introduced at the 39 end of the construct. Details of the
cloning steps are available upon request. Using Gateway cloning,
the MYOD1 cDNA was transferred to the PB-TAC-ERN
destination vector as indicated in Fig. 1a, to yield the transposon
PB-MyoD1.
Plasmid DNA for transfection was prepared using a QIAprep
Spin Miniprep Kit (Qiagen). Non-diseased control hiPSCs and
MM-hiPSCs were seeded onto mitomycin C-treated SNL feeder
cells [1] in a 6-well culture dish. The next day, 1 mg destination
vector and 1 mg PBase plasmid [19] were transfected into hiPSCs
with FuGENE HD (Roche), according to the manufacturer’s
protocol. Forty-eight hours after transfection, 100 mg/mL G418
(Nacalai Tesque) was added to select for stable Tet-MyoD1
transposition, clones were picked, and the appropriate MyoD-
hiPSC clones with high mCherry expression selected.
Overexpression of DYSFERLIN in MM Patient-derived
iPSCs
Full-length DYSF cDNA was kindly provided by the Jain
Foundation. The DYSF cDNA was Gateway cloned into a PB-
based, EF1a promoter-driven constitutive expression vector which
co-expresses puromycin resistance (PB-Dysferlin). MyoD-MM-
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hiPSCs were seeded onto mitomycinC-treated SNL-PH feeder
cells (resistant to neomycin, puromycin, and hygromycin). The
next day, 1 mg of both PB-Dysferlin and PBase [19] plasmids were
transfected into MyoD-MM-hiPSCs by using FuGENE HD
(Roche), as described above. Forty-eight hours after transfection,
100 mg/mL G418 (Nacalai Tesque) and 1 mg/mL Puromycin
(Nacalai Tesque) were added to select for cells carrying both the
Tet-MyoD and PB-Dysferlin vectors. After selection, MyoD-
MM+Dysferlin hiPSC clones displaying DYSFERLIN expression
were selected by western Blotting.
Differentiation of MyoD-hiPSCs
MyoD-hiPSCs were seeded onto CollagenI (Iwaki) or Matrigel
(BD Biosciences) coated dishes without feeder cells. Matrigel was
diluted 1:50 with primate ES medium. MyoD-hiPSCs were
trypsinized and dissociated into single cells. The cell number
plated ranged from 2.06105 to 1.06106 per 10cm2. Culture
medium was changed to human iPS medium without bFGF and
with 10 mM Y-27632 (Nacalai Tesque). After 24 h, 1 mg/mL
doxycycline (LKT Laboratories) was added to the culture medium.
After an additional 24 h, culture medium was changed to
differentiation medium composed of alpha Minimal Essential
Medium (aMEM; Nacalai Tesque) with 5% KSR (Invitrogen),
50 mU/L Penicillin/50 mg/L Streptomycin (Invitrogen), and
100 mM 2-Mercaptoethanol (2-ME). After an additional 5 days,
culture medium was changed to DMEM with 5% horse serum
(Sigma), 50 mU/L Penicillin/50 mg/L Streptomycin, 10 ng/mL
recombinant human insulin-like growth factor 1 (Peprotech),
2 mM L-Glutamine and 100 mM 2-ME. Approximately 2 days
later, myogenic properties were assessed.
Fluorescence Activated Cell Sorting Analysis of mCherry
Positive Cells
Doxycycline-treated cells were washed in Phosphate buffered
saline (PBS) and incubated for 5 min with 0.25% Trypsin to
dissociate into single cells. After cells were counted, they were
suspended in Hank’s balanced salt solution (Life technologies),
supplemented with 1% BSA at 1.06106 cells/100 mL and
analyzed on an LSR Fortessa (BD Biosciences) for the expression
of mCherry.
RNA Isolation and Reverse Transcription
Total RNA was isolated using Sepazol (Nacalai Tesque)
according to the manufacturer’s protocol. Residual genomic
DNA was digested and removed using DNase I (Invitrogen)
treatment. First strand cDNA was synthesized using the Super-
script III First-Strand Synthesis System (Invitrogen) and random
hexamer primers or oligo (dT) according to experimental aims.
Reverse transcription and conventional PCR were performed as
described previously [1]. Quantitative PCR was performed using
probe sets, SYBR Green (Applied Biosystems), and Step One
thermal cycler (Applied Biosystems). b-actin was used as an
internal controls. For standardization, we set the value of the d0,
d5 or d7 sample as the control value ( = 1.0). Primers used in this
study are listed in Table S1.
Transplantation Studies
All mouse experiments were carried out according to protocols
approved by the Animal Research Committee of Kyoto Univer-
sity. The committee specifically approved these animal studies.
NOD/Scid mice were purchased from Charles River Laborato-
ries, and were mated with DMD-null mice (which do not express
DYSTROPHIN) to generate the NOD/Scid-DMD mice used for
in vivo transplantation studies. Mice were anesthetized with diethyl
ether and injured with cardiotoxin before intramuscular cell
transplantation. Twenty-four hours after cardiotoxin damage, d6
Dox-treated MyoD-hiPSCs (1.06106–9.56106 cells per 50 mL
10% Matrigel in aMEM) were injected into left TA muscles. All
mice used in this study were humanely sacrificed 28 days after
transplantation and tissue samples were collected. Collected
samples were embedded into a pedestal of tragacanth gum.
Engrafted muscles were frozen in isopentane cooled in liquid
nitrogen. Serial cryosections (10–20 mm) were collected. Tissue
cryosections were fixed and stained as described previously [44].
Briefly, tissue cryosections were fixed using 4% paraformaldehyde
(PFA)/PBS for 20 min. Samples were blocked with 1% Goat
serum (Sigma), 0.1% Bovine serum Albumin (Sigma), 0.2% Triton
X-100 (Nacalai Tesque)/PBS for 60 min. Samples were incubated
with primary antibodies for 16–18 h at 4uC. Next day, samples
were washed 3 times in PBS and incubated with secondary
antibodies for 1 h at room temperature. 4,6-Diamidino-2-
phenylindole (DAPI; 1:5000) was used to counter-stain nuclei.
PermaFluor (Thermo Scientific) was used as a mounting agent.
Samples were observed by LMS710 confocal microscopy (Carl
Zeiss).
Teratoma Formation Assay
For teratoma formation, sub-confluent undifferentiated human
iPSCs were harvested and resuspended in maintenance medium
containing 50% Matrigel. Human iPSCs were injected into tibialis
anterior muscles of NOD/scid mice by using pre-chilled syringe
with a 27G needle. Mice were sacrificed for assays 4 weeks after
transplantation.
Co-culture with C2C12 Cells
Differentiated MyoD-hiPSCs were co-cultured with a C2C12
cell line which expresses GFP constitutively from the CAG
promoter (kindly provided Dr. Kurisaki, Department of Growth
Regulation, Institute for Frontier Medical Sciences, Kyoto
University). MyoD-hiPSCs were differentiated for 7 days accord-
ing our protocol. On d7, medium was replaced with DMEM
supplemented with 5% horse serum, and 1.06105 C2C12 cells
were seeded onto MyoD-hiPSCs. Bio Station CT (Nikon) was used
for time-lapse observation of co-cultured samples. The duration of
image acquisition was 1 h.
Immunohistochemistry of Cultured Cells
Cells were fixed and stained as described previously [1]. Briefly,
cells were fixed using 2% PFA/PBS. Samples were blocked with
5% Blocking One (Nacalai Tesque)/PBS for 30 min and then
incubated with primary antibodies diluted in 5% Blocking One/
PBS for 16–18 h at 4uC. Next, samples were washed 3 times in
PBS and incubated with secondary antibodies diluted in 5%
Blocking One/PBS for 1 h at room temperature. DAPI
(1:5000;Sigma) was used to counter-stain nuclei. Antibodies are
listed below. For mitochondrial staining, MitoTracker Red
CMXRos (Invitrogen) was used according to the manufacturers
protocol. Samples were observed with a BZ-9000E (Keyence).
Western Blotting
Cells were harvested and analyzed as described previously [1].
Briefly, semiconfluent cells were lysed in RIPA buffer (50 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40 (NP-40), 1%
sodium deoxycholate, and 0.1% SDS), supplemented with pro-
tease inhibitor cocktail (Roche). Cell lysates (10 mg) were separated
by electrophoresis on 8% or 12% SDS-polyacrylamide gel and
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transferred to a polyvinylidine difluoride membrane (Millipore).
The blot was blocked with TBST (20 mM Tris-HCl, pH 7.6,
136 mM NaCl, and 0.1% Tween-20) containing 1% skim milk
and then incubated with primary antibody solution at 4uC
overnight. After washing with TBST, the membrane was
incubated with secondary antibody for 1 h at room temperature.
Signals were detected with Immobilon Western chemiluminescent
HRP substrate (Millipore) and ChemiDoc XRS+imaging system
(BIO-RAD). Antibodies are listed below.
Primary and Secondary Antibodies
Primary antibodies used in this study were as follows: rat, anti-
Laminin monoclonal antibody (mAb; 1:15; Alexis), mouse Anti-
human Myosin heavy chain mAb (MF20; 1:400; R&D), mouse
anti-myogenin mAb (F5D; 1:400; Santa Cruz), rabbit anti-MyoD
polyclonal antibody (pAb; M-318, 1:400; Santa Cruz), mouse anti-
human Spectrin mAb (1:100; Leica), mouse anti-human nuclei
mAb (1:200; Millipore), mouse anti-alpha skeletal muscle actin
mAb (1:200; Acris), rabbit anti-Creatine Kinase M pAb (Y14;
1:100; Bioworld Technology), mouse anti-Dysferlin mAb (NCL-
Hamlet, 1:25; Leica), mouse anti-Dystrophin mAb (NCL DYS1,
1:100; Leica), mouse anti-SSEA-4 mAb (1:100; Millipore), mouse
anti-TRA-1-81 mAb (1:100; Millipore), and mouse anti-Nanog
mAb (1E6C4, 1:2000; Cell Signaling).
Secondary antibodies used in this study were as follows: Alexa
Fluor 488 conjugated goat-anti-rabbit or mouse IgG, Alexa Fluor
568 conjugated goat-anti- rabbit or mouse IgG (1:500; Invitrogen),
and HRP conjugated goat-anti-mouse IgG (1:200 for IHC, 1:2000
for western blotting; Vector).
Statistical Analysis
Differences between samples were assessed by using the
Student’s two-tailed t test for independent samples.
Electron Microscopy
Samples were chemically fixed and observed by Tokai Electron
Microscopy, Inc. according to their protocol (Tokai Electron
Microscopy, Inc.). Briefly, Samples were fixed with 2% PFA/PBS,
2% glutaraldehyde (GA) in 0.1 M phosphate buffer (Pb), pH 7.4 at
37uC and put them into a refrigerator (4uC) for 30 min.
Thereafter, they were fixed with 2% GA in 0.1 M Pb at 4uC
overnight. After these fixation the samples were rinsed 3 times with
0.1 M Pb for 30 min each, followed by post fixation with 2%
osmium tetroxide (OsO4) in 0.1 M Pb at 4uC for 1 h.
The samples were dehydrated through a series of graded
ethanol (50%, 70%, 90%, and 100%). The schedule was as
follows: 50% and 70% for 5 min each at 4uC, 90% for 5 min at
room temperature, and 3 changes of 100% for 5 min each at room
temperature.
The samples were transferred to a resin (Quetol-812; Nisshin
EM Co., Tokyo, Japan), and polymerized at 60uC for 48 h.
The blocks were ultra-thin sectioned at 70 nm with a diamond
knife using a ultramicrotome (ULTRACUT UCT; Leica) and
sections were placed on copper grids. They were stained with 2%
uranyl acetate at room temperature for 15 min, and then rinsed
with distilled water followed by being secondary-stained with Lead
stain solution (Sigma-Aldrich Co.,) at room temperature for 3 min.
The grids were observed by a transmission electron microscope
(JEM-1200EX; JEOL Ltd.,) at an acceleration voltage of 80 kV.
Digital images (204862048 pixels) were taken with a CCD camera
(VELETA; Olympus Soft Imaging Solutions GmbH).
Microarray
Total RNA from each condition was obtained from samples by
using the RNeasy Mini Kit (Qiagen) according to the manufac-
turer’s instructions. The quality of RNA samples were determined
to be sufficient for Microarray analysis by using the Agilent RNA
6000 Nano Assay (Agilent Technologies). After confirming the
quality of RNA, cRNA was synthesized on day one. On d2, cDNA
was synthesized and purified. In vitro transcription and biotin
labeling, and hybridization to the GeneChip ST Array (Affyme-
trix) were performed according to Affymetrix protocols on d3 and
4. Samples were loaded onto a Fluidics station (Affymetrix) and
their signals were analyzed.
Microarray Data Analysis
Affymetrix CEL files were imported into GeneSpringGX
11.5.1. Probe intensities were normalized, and expression signals
of all genes (probe sets) were calculated using RMA 16 as
implemented in GeneSpring software. The data were grouped into
those of undifferentiated hiPSCs, MyoD-hiPSCs derived myo-
cytes, and Hu5/E18 derived myocytes. Upregulated genes were
identified by at least 2-fold changes. A heat map was created using
a clustering function algorithm of on both entities and conditions.
Distance metric was Euclidean. Linkage rule was single. Myogenic
upregulated genes were assembled arbitrarily. As statistical
analysis, multiscale bootstrap clustering was performed.
siRNA Transfection
The siRNAs targeting T, TBX6 and a scrambled negative
control were purchased (Sigma, SASI_Hs01_00221962, SA-
SI_Hs01_00166068 and SIC-001-10). siRNA (50 nM) was
transfected into hiPSCs seeded at a density of 2.0 to 3.06105
cells per 10cm2 on d0 and d3, respectively, using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s protocol.
Membrane Repair Assay
Membrane repair assays were performed using differentiated
myotubes as described previously [17]. Briefly, membrane damage
was induced in the presence of FM1-43 dye (2.5 mM; MolecularP-
robes) with a two-photon confocal laser-scanning microscope
(LSM710NLO; Zeiss) coupled to a 10-W Argon/Ti:sapphire laser.
Images were captured beginning 20 s before (t = 0) and for 3 min
after irradiation at 10 s intervals. For every image taken, the
fluorescence intensity at the site of damage was measured with
Zeiss LSM 710NLO imaging software.
Electrical Stimulation
Electrical stimulation was performed using differentiated
MyoD-hiPSCs at around d14 by using C-Dish (ION Optics) as
previously described [45]. We loaded electrical voltage with the
electric stimulator (Uchida Denshi) at 100 V onto differentiated
myotubes for 3 msec at repeated 1 s intervals.
Supporting Information
Figure S1 Evaluation of pluripotency of MyoD-hiPSCs.
(a) Immunohistochemistry of undifferentiated markers. Scale
bar = 100 mm. (b) RT-PCR analysis for undifferentiated markers.
(c) Teratoma formation assay from MyoD-hiPSCs and empty
vector transduced hiPSCs. H&E staining of teratoma formed in
TA muscle from NOD/scid mouse. Three germ layers formed in
teratoma were shown in each panel, respectively. Arrows indicate
each germ layer, respectively. Scale bars = 100 mm.
(TIF)
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Figure S2 Evaluation for MyoD-hiPSC clones. (a) Expres-
sion of mCherry which is synonymous with exogenous MyoD1
driven by Dox treatment for 24 h. (b) RT-PCR analyses of MyoD-
hiPSC clones. Cloned MyoD-hiPSCs had no leaky expression of
exogenous MyoD1 without Dox, while they could express
exogenous MyoD1 24 h after Dox addition. Endogenous MYOD1
could be promoted 96 h after Dox addition.
(TIF)
Figure S3 Other myogenic induction methods by SB-
OGs system or changing Dox-addition days. (a) Protocol of
myogenic induction via EB outgrowth. (b) Expression of mCherry
and immunohistochemistry of MHC. Scale bars = 100 mm. (c)
Protocol of changing the timing of dox-addition. (d) The
percentage of MHC positive cells per total cells. **p,0.01.
(TIF)
Figure S4 Expression of premyogenic mesodermal
markers. Quantitative real time PCR for premyogenic markers
was performed during MyoD-hiPSC differentiation in B7 #9
MyoD-hiPSC clone with (gray bars) or without (black bars) Dox
administration (n= 3). Data are shown as the mean 6 SD. The
data were standardized by b-actin using embryoid body. The data
on d5 or d7= 1. *p,0.05, **p,0.01, respectively.
(TIF)
Figure S5 Suppression of mesodermal markers by
siRNA. The siRNA reagent targeting T or TBX6 was added to
differentiation culture of MyoD-hiPSCs (clone B7 #9) at d0 or d3
(a, b). Quantitative real time PCR was then performed on d3 (a)
or d5 (b) (n = 3). The expression of PAX3 was suppressed by
siRNAs for both T and TBX6. *p,0.05 (c) The expression of
MHC in differentiated MyoD-hiPSCs with or without siRNA
treatment on d9. Scale bar = 100 mm. (d) Percentage of MHC
positive cells 9 days after differentiation with or without siRNA
treatment in B7 #9 MyoD-hiPSC clone (n= 3).
(TIF)
Figure S6 Multiscale bootstrap clustering for the data
from microarray. The number of repeated calculation was
1000 times. Abbreviated words ‘‘AU’’ and ‘‘BP’’ means ‘‘appor-
oximately unbiased p-value’’ and ‘‘bootstrap probability,’’ re-
spectively. Distance means correlation. Cluster method was
average.
(TIF)
Figure S7 Confirmation of the data obtained from
microarray by quantitative real time PCR. (a) Relative
gene expression of transcription factors which are significant in
microarray analyses. Data are listed as mean 6 S.D. The data
were standardized by b-actin using teratoma. The data on d0=1.
The data in Endo-MYOD1, MYOGENIN, MEF2C and SIX1 were
expressed with logarithmic Y axes because differentiated cells
showed extremely high values, respectively. **p,0.01.
(TIF)
Figure S8 Fusion potential in vivo. Immunohistochemistry
of TA muscles from NOD/Scid-DMD mice after 28 days after
transplantation of d6 MyoD-hiPSCs. Scale bars = 20 mm. (a)
Human Spectrin expression (red) was detected along with Laminin
(green). (b) Human DYSTROPHIN expression (green) was
detected along with Laminin (white).
(TIF)
Figure S9 Teratoma formation assay from MyoD-MM
hiPSCs. (a) H&E staining of teratoma formed in TA muscle from
NOD/scid mouse. Scale bar = 100 mm. (b) H&E staining of three
germ layers formed in teratoma. Arrows indicate each germ layer,
respectively. Scale bars = 100 mm.
(TIF)
Table S1 PCR-primers were listed for both RT-PCR
and quantitative real-time RT-PCR.
(DOCX)
Movie S1 The MyoD-hiPSCs changed their shape to
spindle-like uniformly during differentiation from d1 to
d7.
(WMV)
Movie S2 Contraction of myofiber derived from MyoD-
hiPSCs at differentiation d14 by electric stimulation.
(WMV)
Movie S3 Fusion of hiPS cells with murine myofiber.
Red shows human and green shows murine derived myogenic
cells.
(WMV)
Movie S4 Membrane repair assay of MyoD-hiPSC de-
rived myofibers from MM patient. Red circle indicates
damaged point.
(WMV)
Movie S5 Membrane repair assay of MyoD-hiPSC de-
rived myofibers from MM patient with DYSFERLIN
over-expression. Red circle indicates damaged point.
(WMV)
Movie S6 Membrane repair assay of MyoD-hiPSC de-
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